First prospective trial shows molecular profiling timely for tailoring therapy
- Posted: May 16, 2013
A clinical trial has shown that patients were willing to undergo an additional cancer biopsy, to seek out the best treatment for their tumor type through analysis to find and target genetic mutations that drive the cancer. Results of the study, CUSTOM, begun at the National Cancer Institute and completed at the Georgetown Lombardi Comprehensive Cancer Center, are being presented at the 2013 annual meeting of the American Society of Clinical Oncology. Researchers at Oregon Health & Science University also participated.
Among the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.